CCG.ai (acquired by Dante Labs)

CCG.ai is a United Kingdom-based startup established in 2016, specializing in Biotechnology and Health Care. With the slogan "Data-Driven Cancer Treatment", CCG.ai is committed to revolutionizing cancer treatment by providing each patient with personalized medication using advanced data analytics. Their software enables data-driven precision oncology and the development of biomarkers indicative of treatment response. The company secured a significant $4.50M fund in a Seed Round investment on 31 December 2018, with prominent investors such as Soma Capital, Y Combinator, AME Cloud Ventures, Refactor Capital, and Romulus Capital. CCG.ai believes that the increasing availability of clinical and genomic data holds transformative potential for cancer treatment. By leveraging this data, the company aims to equip oncologists with the necessary insights to make informed decisions about medication, thereby improving patient outcomes. With a strong focus on leveraging technology and data to revolutionize oncology, CCG.ai has positioned itself at the forefront of the rapidly advancing field of precision medicine.